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Summary
 
Three different HLA-A2.1 monochains were engineered in which either the human or mouse
 
 
 
2-microglobulin (
 
 
 
2m) is covalently linked to the NH
 
2
 
 terminus of the heavy chain by a 15–
amino acid long peptide: HHH, entirely human, HHD, with the mouse H-2D
 
b
 
 
 
 
 
3, transmem-
brane, and cytoplasmic domains, and MHD, homologous to HHD but linked to the mouse 
 
 
 
2m
 
b
 
.
The cell surface expression and immunological capacities of the three monochains were com-
pared with transfected cells, and the selected HHD construct was introduced by transgenesis in
H-2D
 
b
 
 
 
/
 
 
 
 
 
 
 
2m
 
 
 
/
 
 
 
 double knockout mice. Expression of this monochain restores a sizable pe-
ripheral CD8
 
 
 
 T cell repertoire essentially educated on the transgenic human molecule. Con-
sequently, infected HHD, H-2D
 
b
 
 
 
/
 
 
 
 
 
 
 
2m
 
 
 
/
 
 
 
 mice generate only HLA-A2.1–restricted CD8
 
 
 
CTL responses against influenza A and vaccinia viruses. Interestingly, the CTL response to in-
fluenza A virus is mostly, if not exclusively, directed to the 58-66 matrix peptide which is the
HLA-A2.1–restricted immunodominant epitope in humans. Such mice might constitute a ver-
satile animal model for the study of HLA-A2.1–restricted CTL responses of vaccine interest.
 
T
 
ransgenic mice expressing unmodified HLA class I
molecules have been derived in many laboratories to
provide a suitable animal model for the study of HLA class
I–restricted CTL responses (1). Despite a few reported suc-
cesses (2–6), these attempts have been relatively disappoint-
ing; when virus infected or stimulated by other HLA class I
alleles, these mice preferentially (most of the time exclu-
sively) develop H-2–restricted CD8
 
 
 
 CTL responses (7–10).
Substitution of the HLA 
 
 
 
3 by the homologous H-2 do-
main significantly improves the recognition and usage of some
(A2.1, B27), however not all (i.e., B7.1, our unpublished
observation), HLA class I molecules (11, 12). Similarly, we
and others have established that recognition and usage of
transgenic HLA class I molecules by mouse CD8
 
 
 
 T lym-
phocytes can be promoted when H-2–restricted responses
are controlled. More importantly, under such circum-
stances, a diversified V
 
 
 
 and V
 
 
 
 TCR mouse repertoire is
mobilized, suggesting a sufficient flexibility for an efficient
usage of human class I molecules (13, 14). However, the
experimental artifices (cross-tolerance, serial stimulations in
vitro with appropriate antigen presenting cells) selected to
favor the HLA-restricted CTL responses in transgenic mice
are not of convenient usage. Therefore, we have derived
mice expressing only HLA class I molecules to force the
mouse CD8
 
 
 
 T cell repertoire, both at the thymic and pe-
ripheral levels, to make use of the transgenic HLA class I
molecules. These mice are H-2D
 
b
 
 and mouse 
 
 
 
2 micro-
globulin (
 
 
 
2m)
 
1
 
 double knockouts and express 
 
 
 
2m–HLA-
A2.1 monochains.
We report in vitro transfection experiments that resulted
in the selection of a human 
 
 
 
2m–HLA-A2.1 (
 
 
 
1
 
 
 
2)–H-2D
 
b
 
(
 
 
 
3 transmembrane cytoplasmic) (HHD) monochain con-
struct to derive transgenic animals. These HHD transgenic,
H-2D
 
b
 
 
 
/
 
 
 
 
 
 
 
2m
 
 
 
/
 
 
 
 double knockout mice are almost de-
void of H-2 class I molecules. Phenotypic and functional
analyses of their peripheral CD8
 
 
 
 T cell repertoire indicate
that HHD monochains support thymic positive selection of
CD8
 
 
 
 CTL and activate virus-specific HLA-A2.1–restricted
CTL in the periphery.
 
Materials and Methods
 
Plasmids.
 
The 2.2-kb EcoRI–BglII fragment encompassing
the promoter and the three first exons from the HLA-A2.1 gene
(10) was subcloned in a modified BglII
 
 
 
 pBluescript (Stratagene,
La Jolla, CA) and site mutagenized to introduce a PstI site at the
 
1
 
Abbreviations used in this paper:
 
 
 
 
 
2m, 
 
 
 
-2 microglobulin; HA, hemagglutinin;
TAP, transporter associated with antigen presentation.
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3
 
 
 
 end of the first exon and a BamHI site at the 5
 
 
 
 end of the sec-
ond exon (HLA-A2.1 PB plasmid). BamHI and MscI restriction
sites were introduced at the 5
 
 
 
 and 3
 
 
 
 ends of human 
 
 
 
2m and
murine 
 
 
 
2m
 
b
 
 cDNA, respectively, corresponding to the mature
form (without leader sequence) of the proteins. A three-partner
ligation was performed between the 5
 
 
 
 PstI (T4 polymerase blunt
ended), 3
 
 
 
 BamHI-digested HLA-A2.1 PB plasmid, the 5
 
 
 
 BamHI
(Klenow blunt ended), 3
 
 
 
 MscI-digested human or murine 
 
 
 
2m
cDNA, and a pair of complementary synthetic oligonucleotides
(Genset, Paris, France) coding for a (Gly
 
4
 
Ser)
 
3
 
 linker with 5
 
 
 
 blunt
and 3
 
 
 
 BamHI cohesive end. Final constructs were verified by
double-stranded DNA sequencing (Sequenase version 2.0; United
States Biochemical, Cleveland, OH). In the final recombinant plas-
mids, super-exon I codes for the HLA-A2.1 leader sequence, the
human or mouse 
 
 
 
2m, a 15 amino acid linker, and the 
 
 
 
1 domain of
HLA-A2.1. A 5.1-kb BglII–BamHI or a 2.3-kb BamHI fragment
containing the fourth to eighth exons and the 3
 
 
 
 untranslated re-
gion of the HLA-A2.1 or H-2D
 
b
 
 genes, respectively, was subse-
quently introduced in the BglII site of this construct. This provided
the entirely human HHH, human 
 
 
 
2m–HLA-A2.1 (
 
 
 
1
 
 
 
2) H-2D
 
b
 
(
 
 
 
3 to COOH terminus) HHD, and mouse 
 
 
 
2m
 
b
 
–HLA-A2.1
(
 
 
 
1
 
 
 
2) H-2D
 
b
 
 (
 
 
 
3 to COOH terminus) MHD coding plasmids.
A control construct was also created introducing the BamHI 3
 
 
 
fragment of the H-2D
 
b
 
 gene in the BglII site of the HLA-A2.1
gene (in wild-type configuration) providing a chimeric (HLA-A2.1
 
 
 
1
 
 
 
2, H-2D
 
b
 
 
 
 
 
3, transmembrane and cytoplasmic) heavy chain.
 
Cells and Transfectants.
 
RMA (transporter associated with an-
tigen presentation [TAP] positive), RMA-S (TAP negative), EL4
(
 
 
 
2m positive), and EL4 S3 Rob (
 
 
 
2m negative) C57Bl/6 (H-2
 
b
 
)
lymphoma cells were maintained in RPMI, 10% FCS. Cells (5 
 
 
 
10
 
7
 
) in 500 
 
 
 
l of PBS were electroporated with 50 
 
 
 
g of plasmid
constructs and 1 
 
 
 
g of pMCS (15) linearized DNA at 250 V and
either 1,500 (RMA, RMA-S) or 1,050 (EL4, EL4 S3 Rob) 
 
 
 
F
using an Easyject gene pulser (Eurogentec, Seraing, Belgium). Af-
ter 24 h, cells were transferred in selective medium containing 1
mg/ml G418 (GIBCO BRL, Paislay, U.K.) and cloned by limit-
ing dilution. Neomycin-resistant clones expressing the monochains
were identified by indirect immunofluorescence using unlabeled
B9.12.1 (anti-HLA class I, F(ab)
 
 
 
2) and goat anti–mouse Ig (F(ab)
 
 
 
2)
FITC-conjugated antibodies and analyzed by flow cytofluorome-
try with a FACScan
 

 
 (Becton Dickinson, San Jose, CA).
 
Immunoprecipitations. Cells (5   106) were washed in me-
thionine- and cystein-free RPMI medium (ICN Biomedicals, Inc.,
Costa Mesa, CA) supplemented with 10% dialyzed FCS and in-
cubated for 45 min at 37 C in 1 ml of the same medium before
labeling for 15 min with 1 mCi of [35S] methionine–cystein mix
(Pro-mix; Amersham, Buckinghamshire, U.K.). Pelleted cells were
lysed in PBS containing 1% BSA and 1% NP-40 (BDH Chemi-
cals, Ltd., Poole, U.K.). Lysates were precleared (2 h, 4 C with
protein A–Sepharose beads) and then incubated overnight at 4 C
with 10  g of purified anti–HLA-A2.1 (BB7.2) mAb. After addi-
tion of protein A–Sepharose beads and further incubation for 2 h
at 4 C, beads were washed four times with 60 mM Tris HCl, pH
7.4, 150 mM NaCl, 0.5% deoxycholic acid, 5 mM EDTA, 1%
NP-40, 0.1% SDS. Proteins were eluted, denatured, and sepa-
rated by SDS-PAGE on 12% gels. Dryed gels were exposed on a
Phosphorimager screen (Molecular Dynamics, Sunnyvale, CA) and
analyzed using Imagequant program (Molecular Dynamics).
Generation of CTL and Cytolytic Assays. HLA-A3 transgenic
C57Bl/6 mice were injected intraperitoneally with 3   107 HLA-
A2.1   human  2m transgenic C57Bl/6 mouse splenocytes. 2 wk
later, splenocytes (5   107) from immunized mice were restimu-
lated in vitro with 3   107 irradiated (2,000 rads) HLA-A2.1  
human  2m transgenic splenocytes for 5 d. Human recombinant
IL-2 (Santa Cruz Biotechnology, Santa Cruz, CA) was added on
day 3 of culture.
Influenza A–specific, HLA-A2.1–restricted HAM 42 CTL
clone generated in HLA-A2.1 transgenic mice (8), was provided
by Dr. V. Engelhard and maintained in vitro by weekly restimu-
lation with HLA-A2.1–positive JY human lymphoblastoid cells,
pulsed with 10 6 M of influenza A matrix 58-66 synthetic pep-
tide GILGFVFTL.
HHD  H-2Db /   2m /  mice were intraperitoneally infected
with either 1,000 hemagglutinin (HA) units (influenza A/PR/8/
34, provided by Dr. J.-C. Manuguerra, Laboratoire de Genetiq
Moleculair des Virus Respiratoir Institut Pasteur, Paris, France) or
107 PFU (vaccinia) viruses. 2–4 wk later, 2.5   107 (influenza A) or
6   107 (vaccinia) splenocytes were restimulated in vitro with 2.5  
107 (influenza A) or 3   107 (vaccinia) irradiated (3,000 rads) synge-
neic red blood cell–depleted splenocytes infected for 1 h with influ-
enza A (10 HA unit for 106 cells) or vaccinia (10 PFU/cell) viruses.
Responder mice were individually tested in a standard cy-
tolytic assay 5 d later. In brief, 106 cells, uninfected or infected
(1,000 HA units of influenza A or 5   107 PFU of vaccinia viruses)
for 1.5 h in medium without FCS and further incubated for 2 h
in medium containing 5% FCS, were subsequently labeled with
100  Ci of sodium [51Cr]chromate for 1.5 h at 37 C and then
washed three times. Cytolytic activity was determined in 4 h
51Cr–release assays using V-bottom 96-well plates containing 5   103
uninfected, influenza A matrix 58-66 peptide-pulsed (10 6 M) or vi-
rus-infected target cells/well in the presence of effector cells from
bulk cultures. Effector/target ratios were as shown in Figs. 3 and 8.
Results are the mean of triplicates calculated as 100   [(experi-
mental   spontaneous release) / (total   spontaneous release)], with
maximal release being determined by lysis of target cells by 1 M HCl.
Generation of H-2Db /  Knockout Mice. A 10-kb HindIII frag-
ment containing the whole H-2Db gene and a 1.9-kb PstI frag-
ment encompassing the 3  part of the third exon, the fourth intron,
and the 5  part of the fourth exon were cloned in pBluescript
(Stratagene) vector. The H-2Db targeting construct was gener-
ated by inserting a 4-kb XbaI 5  fragment from the H-2Db gene
and a 1.3-kb KpnI 3  fragment from the PstI subclone in the cor-
responding restriction sites of the pGNA vector polylinker (16).
CGR-8 embryonic stem cells were cultured as described (17) in
the absence of feeder cells in medium supplemented with murine
differentiation inhibiting factor and/or leukemia inhibiting factor.
To isolate homologous recombinants, 108 cells were electroporated
in 900  l of PBS with 150  g of SpeI-linearized plasmid DNA at
800 V and 3  F, using a Bio Rad Labs. (Hercules, CA) gene
pulser and selected after 24 h in the presence of G418 (175  g/ml).
28 pools of 12 G418-resistant clones were screened by PCR, using
a pGNA-specific 5  (CAGCAGAAACATACAAGCTGTC) and a
H-2Db exon 5–specific 3  (AACGATCACCATGTAAGAGT-
CAGT) pair of oligonucleotides, resulting in the amplification of
the expected 1.6-kb fragment for 18 pools. The homologous re-
combination event, detected by hybridization of a 5.6-kb HindIII
fragment with a 3  noncoding BamHI-HindIII probe, was con-
firmed in six colonies by Southern blot analysis. Two out of five
clones injected into C57BL/6 blastocysts gave rise to germline
transmission of the mutation. Germline chimeras were mated
with C57Bl/6 females and pups were typed by Southern blot
analysis of tail DNA. Heterozygous offspring were backcrossed to
C57BL/6 animals and then intercrossed at the N2 generation to
give rise to two independent H-2Db /  homozygous strains. Inac-
tivation of the H-2Db gene was confirmed by Southern blot anal-
ysis on tail DNA and immunofluorescence assay.2045 Pascolo et al.
Generation of HHD Transgenic Mice. A 4-kb SalI–NotI frag-
ment containing the HHD construct was injected into C57Bl/6  
SJL oocytes. Transgenic mice identified by Southern blot analysis
of tail DNA and immunofluorescence assay were crossed with
H-2Db /   2m /  double knockout mice.
FACS Analysis of the Peripheral T Cell Repertoire of HHD  H-2Db / 
 2m /  Knockout Mice. Expression of the HHD monochain
and lack of H-2Db and H-2Kb were documented by indirect im-
munofluorescence analyses using B9.12.1 (anti–HLA class I),
B22.249.R.19 (anti–H-2Db), and 20.8.4S unlabeled mAb, de-
tected with F(ab) 2 FITC-conjugated goat anti–mouse IgG. Per-
centages of single CD4  and CD8  T lymphocytes were deter-
mined by double staining using phycoerythrin-labeled anti–mouse
CD4 (CALTAG Labs., South San Francisco, CA) and biotinylated
anti–mouse CD8 (CALTAG Labs.) detected with streptavidin–
Perc-P (CALTAG Labs.). Expression of the different V  TCR were
similarly analyzed using phycoerythrin-labeled anti-CD8 mAb (Phar-
Mingen, San Diego, CA) and purified, FITC-labeled V 2 (B.20.6),
V 3 (KJ.25), V 4 (KT.10.4), V 5.1,.2 (MR.9.4), V 6 (44.22),
V 7 (TR 130), V 8.1,.2,.3 (F.23.1), V 9 (MR. 10.2), V 10
(B.21.5), V 11 (RR.3.15), V 13 (MR.12.4), and V 17 (KJ.23.1)-
specific mAb. Splenocytes from three individual Db / ,  2m / ,
HHD , or HHD  mice were red blood cell depleted and en-
riched in T lymphocytes by wheat germ agglutinin (Sigma
Chemical Co., St Louis, MO) precipitation of B lymphocytes and
NK cells as described (18). Staining of 106 cells was performed in
100  l of PBS with 0.02% sodium azide for 30 min on ice. Puri-
fied mAb or F(ab) 2 were used at 10  g/ml and F(ab) 2 FITC-
conjugated goat anti–mouse IgG was used 1:100 diluted. A total
of 25,000 1% paraformaldehyde-fixed cells per sample was sub-
jected to one- or two-color analysis on FACScan.
Results
Design of HLA-A2.1 Monochains. Recombinant genes en-
coding HLA-A2.1 monochains were engineered, as illustrated
in Fig. 1, by introducing between the first and second exon
of the genomic HLA-A2.1 gene a  2m cDNA (deprived of
from the nucleotides corresponding to the leader sequence)
and a pair of synthetic oligonucleotides encoding a 15 resi-
due (Gly4Ser)3 peptide linker, as already described (19, 20).
The first intron of the HLA-A2.1 gene was therefore de-
leted resulting in a chimeric exon 1 that codes for the
leader sequence of HLA-A2.1, the  2m domain, the pep-
tide linker, and the HLA-A2.1  1 domain. Three different
HLA-A2.1 monochains were engineered: HHH, fully hu-
man; HHD, containing the mouse H-2Db  3, transmem-
brane, and cytoplasmic domains; and MHD, homologous
to HHD, with the mouse instead of the human  2m. All
constructs, verified by sequencing, encode monochains in
which the amino acid sequence of the leader, mature  2m,
and  1 domains are totally conserved.
Expression in RMA Cells. By indirect immunofluores-
cence analysis of RMA lymphoma transfected cells (Fig. 2 A),
cell surface expression of HHH, HHD, and MHD mono-
chains was compared to the cell surface expression of their
heterodimeric counterparts. Despite selection of transfec-
tants expressing similar amounts of monochain transcripts
(as judged by semiquantitative PCR, data not shown) cell
surface expression reaches the level of control cells only for
HHH and HHD monochains. Surtransfection of MHD-
expressing cells with the human  2m gene corrects the de-
fect of cell surface expression of this monochain (data not
shown), suggesting, in spite of their covalent linkage, poor
interaction between the mouse  2m and the HLA-A2.1  1
and   2 domains (21, 22). Tested with a panel of nine
HLA-A2.1–specific mAb (data not shown), the three mono-
chains exhibited normal serological reactivities, indicating that
the peptide linker does not markedly alter the overall three-
dimensional structure of the HLA-A2.1 molecule.
HLA-A2.1 monochains were exclusively detected as 60-kD
proteins by immunoprecipitation using HLA-A2.1–specific
BB7.2 mAb and PAGE analysis, suggesting that the fused
molecules are not proteolytically separated after synthesis
(Fig. 2 B).
Finally, recognition by mouse CTL of the monochains
was evaluated (Fig. 3). An influenza A matrix-specific, HLA-
A2.1–restricted CTL clone (HAM 42; 14) was first tested on
target cells pulsed with synthetic 58-66 influenza matrix pep-
Figure 1. Design of the monochains. (A) Schematic representation of
the monochains. Open area, human origin; hatched area, mouse origin.
The thicker line corresponds to the 15 amino acid linker. (B) Linear rep-
resentation of the final constructs. Open boxes, coding sequence of hu-
man origin; hatched boxes, coding sequences of mouse origin; closed
box, 1.6-kb EcoRI–BamHI fragment from pBR328 plasmid. (C) Nucle-
otide and amino acid sequences of the created junctional regions.2046 HHD Transgenic H-2Db /   2m /  Double Knockout Mice
tides. This CTL clone killed HHH-, HHD-, and MHD-
RMA monochain transfectants and RMA cells expressing
heterodimeric HLA-A2.1   human  2m molecules with
approximately the same efficiency (Fig. 3 A). Expression by
the MHD and HHD monochains of a mouse H-2Db  3
Figure 2. Monochain expres-
sion in RMA cells. (A) Flow cy-
tometric analysis of RMA cells
expressing HLA-A2.1 monochains
or their heterodimeric counter-
part, either wild-type (HLA-A2.1,
A2) or chimeric (HLA-A2.1
 1 2, H-2Db   3, transmem-
brane, cytoplasmic, A2Db) class
I heavy chains associated with ei-
ther human (RMA/A2/h 2m,
RMA/A2Db/h 2m) or mouse
(RMA/A2Db)   2m. HLA class
I–specific B9.12.1 unlabeled mAb
was detected with F(ab) 2 FITC-
conjugated goat anti–mouse IgG.
Negative control was RMA un-
transfected cells. Results are ex-
pressed in fluorescence intensity
(x-axis, log scale) and relative cell
number (y-axis). (B) Untrans-
fected and transfected RMA cells
were [35S]methionine labeled as
described in Materials and Meth-
ods, and immunoprecipitations
were carried out with HLA-A2-
Aw69–specific BB7.2 mAb.
Figure 3. Recognition of the monochains by allospecific or influenza
A matrix-specific CTL. 51Cr–release assays were performed as described
in Materials and Methods. Spontaneous release was  15% for all targets.
(A) Influenza A matrix-specific, HLA-A2.1–restricted CTL clone HAM
42 was tested against MHD, HHD, HHH monochains and heterodimeric
HLA-A2.1   human  2m-transfected RMA target cells, without peptide
(circles) or loaded (triangles) with 10 6 M synthetic peptide (amino acid 58-66
from the influenza A matrix protein). (B) HLA-A2.1 allospecific CTL
from HLA-A3 transgenic mice isolated as described in Materials and Methods
were similarly tested against the same target cells. Background lysis of
nontransfected target cells was  3% at all E/T ratios (data not shown).
domain that should facilitate their interaction with mouse
CD8 molecules did not result in more efficient lysis, under
our experimental conditions, by HAM 42 clone. CD8-
independent recognition of target cells has been observed
for some CTL clones, possibly related to the expression by
these clones of TCR of high affinity (23). Therefore, to
more precisely evaluate the impact of the mouse  3 do-
main on the recognition by mouse CTL of the HLA-A2.1
monochains, the same target cells were tested with poly-
clonally activated, HLA-A2.1–specific CTL, raised by im-
munization of C57BL/6 HLA-A3 transgenic mice with
splenocytes of C57BL/6 HLA-A2.1   human  2m double
transgenic mice. Such polyclonally activated CTL specifi-
cally lyse HLA-A2.1–positive human cell line (JY), HLA-
A2.1 transfected P815(H-2d), and RMA(H-2b) murine cell
lines (data not shown), as well as the three monochain
transfectants. However, MHD and, more strikingly, HHD
monochain transfectants were more efficiently recognized
(Fig. 3 B). Thus, as already documented for heterodimeric
HLA-A2.1 molecules (12), recognition by mouse CTL of
the HLA-A2.1 monochains is facilitated by the introduc-
tion of a mouse  3 domain.2047 Pascolo et al.
Altogether, these in vitro studies of transfected cells
show that the three HLA-A2.1 monochains are cell-surface
expressed, serologically not altered, bind exogenous pep-
tides, and are recognized by CTL. This suggests that they
have a three-dimensional structure similar to wild-type
heterodimeric molecules. They further argue for the selec-
tion of HHD molecules that are efficiently cell-surface ex-
pressed and that interact with the mouse CD8 molecules.
Peptide-dependency of Cell Surface Expression. Monochain
constructs were introduced in TAP-deficient RMA-S cells
to test whether cell surface expression of HLA-A2.1 mono-
chains would be promoted at 25 C and stabilized at 37 C
by the fixation of exogenous peptides (24). The results of
these experiments are illustrated in Fig. 4. Cultivating
transfected RMA-S cells at 25 C resulted in enhanced cell-
surface expression of HHH, HHD, and, to a lesser extent,
MHD monochains, which were stabilized at 37 C by the
fixation of the 58-66 influenza matrix peptide. Thus, HLA-
A2.1 monochains exhibited the same peptide dependency
for stabilization as their heterodimeric counterparts. More-
over, at the surface of RMA-S transfectants, a relatively high
basal expression of HLA-A2.1 monochains was observed at
37 C in the absence of exogenous peptides, suggesting, as es-
tablished for wild-type heterodimeric HLA-A2 (25, 26), that
HLA-A2.1 monochains in TAP-deficient cells bind a sig-
nificant amount of hydrophobic leader peptides in the en-
doplasmic reticulum.
Monochain Expression in  2m-deficient Cells.  2m-deficient
EL4 S3 Rob cells (27) were stably transfected with the
monochain constructs to precisely evaluate the possibility
that heavy chain–linked  2m could promote the reexpres-
sion of endogenous H-2 class I mouse heavy chains. To be
in a situation analogous to that of  2m knockout mice, se-
lected clones of transfectants were cultured in medium sup-
plemented with FCS deprived of bovine  2m by extensive
immunoadsorption on a bovine  2m-specific, CAB.297 mAb
column (28).
As illustrated in Fig. 5, we found limited, however re-
peatedly observed, reexpression of H-2Db, a conclusion
Figure 4. Peptide dependency of stable cell surface expression of the
monochains. Cell surface–expressed monochains were stained with HLA
class I–specific B9.12.1 unlabeled F(ab) 2 mAb detected with F(ab) 2 FITC-
conjugated goat anti–mouse IgG. Results are expressed in fluorescence
intensity (x-axis, log scale) and relative cell number (y-axis). (Left) Cell
surface expression of monochains after overnight culture at 37 or 25 C.
(Right) Stabilization of cell surface expression of HLA-A2.1 monochains
after overnight culture at 25 C, addition of 10 5 M, 10 6 M, or no syn-
thetic peptide (amino acid 58-66 from influenza A virus matrix protein;
closed histograms) and subsequent incubation for 4 h at 37 C.
Figure 5. Expression of the monochains in  2m-deficient cells. Un-
transfected, HLA-A2.1   human  2m-, HHD-, or HHH-transfected
 2m  EL4 S3 Rob cells, cultured in medium containing 3% FCS and
fully depleted in bovine  2m by immunoadsorption on a bovine  2m-
specific (CAB.297) mAb column, were stained with B22.249.R.19 (H-
2Db 1 2–specific), 20.8.4S (H-2Kb 1 2-specific), or B9.12.1 (HLA
class I–specific) unlabeled mAb, detected with F(ab) 2 FITC-conjugated
goat anti–mouse IgG (goat anti–mouse FITC). Negative controls were
with no first mAb. Results are expressed in fluorescence intensity (x-axis,
log scale) and relative cell number (y-axis).2048 HHD Transgenic H-2Db /   2m /  Double Knockout Mice
based on the fact that the B22.249.R.19 mAb reacts with
the  1 2 H-2Db domains. Since H-2Db molecules are fur-
thermore susceptible to reach cell surfaces in the absence of
endogenous  2m (29), we concluded that the production
of HLA-A2.1 monochain transgenic mice should be associ-
ated with the destruction of both mouse  2m and H-2Db
genes, by homologous recombination. Altogether, these in
vitro studies using transfected cells show the integrity and
the functional capacities of HLA-A2.1 monochains and led
us to select the HHD construct for the production of the
HLA-A2.1 monochain transgenics mice.
Expression of HHD Monochains in H-2Db /  Mouse
 2m /  Double Knockout Mice. A targeting construct in
which exons 1, 2, and 3 of the H-2Db gene were replaced
by a plasmid conferring resistance to G418, was electropo-
rated in CGR-8 embryonic stem cells (30), and homologous
recombinants were identified at the clonal level by PCR and
Southern blot analyses (Fig. 6). After blastocyst injection
and reimplantation, chimeric mice were obtained, which
gave germline transmission of the targeted gene. H-2Db / 
homozygous animals were then produced. These animals
show no profound quantitative and qualitative modifica-
tions of their CD8  T cell repertoire (data not shown, Per-
arnau et al., manuscript in preparation). These H-2D / 
mice were crossed with  2m /  knockout mice (31) to
derive H-2Db /   2m /  double mutants. Since initial at-
tempts to use these mice for transgenesis failed, C57BL/6  
SJL were used as recipients. Transgenic animals identified
by Southern blotting and serological analyses were crossed
with H-2Db /   2m /  knockout mice to derive HHD
(heterozygous) H-2Db /   2m /  experimental animals.
Weak (compared to endogenous H-2 class I molecules in
normal mice), but significant, expression of the transgenic
HHD molecules on unactivated peripheral T lymphocytes
was documented by indirect immunofluorescence and FACS
analysis. Under similar conditions, no H-2Kb and H-2Db
molecules could be detected (Fig. 7 A). This expression of
HHD monochains partially restores the peripheral pool of
CD8  T lymphocytes (5.5% of the T lymphocytes instead
of 20–30% in normal mice). More importantly, testing the
10 available anti-V  mAb, it appeared, as illustrated in Fig.
7 B for V 8, that these CD8  T lymphocytes exhibited a
diversified TCR repertoire. By comparison with H-2Db / 
 2m /  double knockout mice, which are almost com-
Figure 6. Disruption of the H-2Db gene. (A) Genomic structure of the
H-2Db gene. Black box, coding exon; hatched box, noncoding exons. The
3  noncoding BamHI–HindIII probe used for Southern blot analysis and
the length of the wild-type HindIII fragment are shown. (B) Restriction
map of the SpeI-linearized targeting vector, which contains a 4-kb Hin-
dIII-XbaI 5  and a 1-kb KpnI–SpeI 3  fragment of the H-2Db gene. (C)
Predicted structure of the targeted H-2Db gene, in which the first three
exons are replaced by the whole plasmid sequence; the 1.6-kb PCR-
amplified diagnostic fragment and the length of the diagnostic 5.6-kb
HindIII fragment generated after recombination are shown. H, HindIII;
B, BamHI; X, XbaI; K, KpnI; Sp, SpeI.
Figure 7. Phenotypical characterization of H-2Db / ,  2m / , HHD
transgenic mice. Flow cytometric analyses were performed on spleen T
lymphocytes from H-2Db / ,  2m / , HHD  (left), or HHD  (right)
mice. (A) Expression of H-2Kb, H-2Db, and HHD molecules detected
with 20.8.4.S, B22.249.R.19, or B9.12.1 mAb, respectively and F(ab) 2
FITC-conjugated goat anti–mouse IgG, negative controls with no first
mAb. Results are expressed in fluorescence intensity (x-axis, log scale) and
relative cell number (y-axis). (B, top) Partial restoration of the peripheral
pool of CD8  T lymphocytes. Double staining was performed with phy-
coerythrin-labeled anti-CD4 (x-axis, log scale) and biotinylated anti-CD8
detected with streptavidin–Perc-P (y-axis, log scale). (Bottom) Peripheral
CD8  TCR repertoire. As illustrated for V 8.1.2.3, double staining was
performed with FITC-labeled anti-V 2 (B.20.6), -V 3 (KJ.25), -V 4
(KT.10.4), -V 5.1,.2 (MR.9.4), -V 6 (44.22), -V 7 (TR 130), -V 8.1,.2,.3
(F.23.1), -V 9 (MR.10.2), -V 10 (B.21.5), -V 11 (RR.3.15), -V 13
(MR.12.4), and -V 17 (KJ.23.1)–specific mAb (x-axis, log scale) and phy-
coerythrin-labeled anti-CD8 mAb (y-axis, log scale).2049 Pascolo et al.
pletely deprived of peripheral CD8  T lymphocytes, these
results suggest that HHD monochains promote CD8  T
cell positive education in the thymus.
CTL Responses of HHD H-2Db /   2m /  Mice. HHD
(heterozygous) H-2Db /   2m /  animals were intraperi-
toneally infected with either vaccinia or influenza A vi-
ruses. 2–4 wk later, splenocytes were restimulated in vitro
with virus-infected syngeneic irradiated splenocytes and
tested 5 d later in a classical 51Cr–release assay.
All animals tested (four out of four for each virus) have
developed virus-specific, HHD-restricted CTL responses
allowing the in vitro killing of virally infected HHD-trans-
fected cells (Fig. 8). No significant lysis was observed test-
ing the effector cells on vaccinia- or influenza A–infected
EL4 cells, indicating that the CTL generated were HLA-
A2.1 restricted. Two additional points are worth mention-
ing. First, these CTL recognized uninfected HHD-trans-
fected cells loaded with the 58-66 influenza A matrix pep-
tide with the same efficiency as infected cells (Fig. 8 B).
Second, the CTL responses appeared strongly CD8 depen-
dent, HHD-transfected cells (as well as their heterodimeric
counterparts) being much more efficiently recognized than
transfectants expressing a fully human molecule.
Discussion
Comparative analyses of the cell surface expression and
CTL recognition of HHH, HHD, and MHD monochains
led to the selection of the HHD construct for the develop-
ment of HLA-A2.1 transgenic mice. Cell-surface expres-
sion of MHD monochains has constantly been found to be
5–10 times lower by FACS analysis. We know, from pulse-
chase and endoglycosidase H digestion experiments, that
MHD monochains egress slowly from the endoplasmic
reticulum. HHH and HHD monochains, by contrast, leave
this cellular compartment as rapidly as HLA-A2.1   hu-
man  2m heterodimers (data not shown). Better interac-
tion with mouse CD8 molecules has been the key element
for the selection of the HHD construct. A similar observa-
tion has already been made analyzing the CTL responses of
transgenic mice expressing, as heterodimers, chimeric HLA-
A2.1  1 2   H-2Kb  3 transmembrane and cytoplasmic
domain heavy chains (12). Further improvement of this in-
teraction might be expected, particularly for some other
HLA class I alleles (i.e., HLA-B7), by site-directed mu-
tagenesis of the  2 residues implicated in the CD8 binding
site (32). Alternatively, one might consider the possibility
of introducing the human CD8   and   chains by trans-
genesis.
Profound reduction in cell surface expression of H-2
class I molecules has been documented serologically after
destruction of mouse  2m gene by homologous recombi-
nation (31, 33). However, studying both  2m  tumor cells
and   2m knockout mice, residual expression of H-2Db
molecules has been described, indicating that a fraction of
functionally conformed H-2Db heavy chains reaches the
cell surface in the absence of  2m (34). Since it was ob-
served ex vivo that HHD monochains promote, to a cer-
tain extent, H-2Db molecule cell surface export, it was of
interest to have HHD molecules expressed in H-2Db / 
and  2m /  double knockout mice. Nevertheless, such mice
cannot be considered as completely devoid of cell surface–
expressed classical H-2 class I molecules. In fetal thymic or-
gan cultures from  2m /  mice, H-2Kb–restricted CTL
can be positively selected in the presence of exogenously
added  2m and peptides (35). Additionally, H-2Kb–specific
CTL have been generated against  2m  cells, and H-2Kb
molecules can be detected at the surface of Con A–stimu-
lated  2m /  splenocytes, implying residual expression of
 2m-free, H-2Kb heavy chains (36–38). This residual ex-
pression might account for the small percentage (0.4%) of
CD8  T lymphocytes observed in H-2Db   2m double
knockout mice (Fig. 7 B). Even if it is generally assumed
that  2m-free H-2Kb heavy chains are expressed in lower
Figure 8. Virus-specific, HLA-A2.1–restricted CTL responses of
H-2Db / ,  2m /  HHD transgenic mice. 2–4 wk after immunization,
CTL were restimulated in vitro for 5 d and 51Cr–release assays were per-
formed. Targets were  2m-deficient (EL4 S3 ), wild type (EL4), HHD,
or HLA-A2.1   human  2m-transfected EL4 S3  and HLA-A2A2Db  
human  2m-transfected RMA cells either uninfected (A and B, closed cir-
cles), vaccinia (A, closed triangles), influenza A (B, closed triangles) infected,
or influenza A matrix (58-66) peptide pulsed (B, open triangles). Spontane-
ous release was  15% for all target cells.2050 HHD Transgenic H-2Db /   2m /  Double Knockout Mice
amounts than  2m-free H-2Db heavy chains, it may be of
interest to derive H-2Kb, H-2Db,   2m triple knockout
mice.
Despite the residual expression of  2m-free H-2Kb
heavy chains and the relatively low expression level (for
which we do not have definitive explanation) of HHD
monochains by HHD (heterozygous) transgenic H-2Db  2m
double knockout mice, the results reported indicate effi-
cient usage of the HLA-A2.1 monochain both at the edu-
cational and effector levels by the mouse CD8  T lympho-
cytes. Expression of the monochain restores a sizable and
diversified CD8  T cell repertoire, supporting the notion
that no significant species bias prevents interactions be-
tween mouse TCR and HLA class I molecules (8, 13). More
complete restoration is anticipated once animals homozy-
gous for the transgene will be isolated. It might be of im-
portance to reach expression levels similar to those ob-
served at the surface of human cells to study CTL responses
against peptides that interact or are recognized with rela-
tively low affinity. In the absence of both H-2Db and
mouse   2m, it must be assumed that most peripheral
CD8  T lymphocytes have been educated in the thymus
on HHD monochains. This should facilitate the study of
HLA class I–restricted responses compared to classical trans-
genic mice. One might hope that the information gained
with these animals will be of human relevance. Two re-
cently reported studies have indicated significant overlap
between HLA-A2.1 transgenic mice and human CTL re-
sponses assaying a large panel of hepatitis C- and hepatitis
B virus-derived T cell epitopes (39, 40). The development in
HHD animals of potent CTL responses against the immuno-
dominant (in HLA-A2.1 individuals) matrix peptide, docu-
mented in this report, also support such possibility. We are
planning to use these animals for a comparative study of the
vaccine potential of the HLA-A2.1–restricted T cell epitopes
already characterized in various human diseases and a com-
parison of the different vaccine strategies.
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